Zarzio^sup ^, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study

• Published in: Supportive care in cancer Vol. 24; no. 5; p. 1991
• Main Authors: Nahon, Sophie, Rastkhah, Mansour, Ben Abdelghani, Meher, Soumoudronga, Ravaka-fatoma, Gasnereau, Isabelle, Labourey, Jean-luc
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer Nature B.V 01.05.2016
• Subjects: Cancer; Chemotherapy; Clinical outcomes; Drug therapy; Leukocytes; Side effects
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-015-2986-0

Purpose Chemotherapy-induced neutropenia is a serious and potentially life-threatening consequence of cancer treatment. Prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) decreases the incidence of febrile neutropenia, the rate of hospitalization, and the use of antibiotics in patients at risk. The aim of this study was to assess efficacy, safety, and use of Zarzio^sup ^--biosimilar of Neupogen^sup ^ (G-CSF; filgrastim)--in prophylaxis of chemotherapy-induced neutropenia in current practice in cancer patients. Methods We conducted an observational, prospective, longitudinal, and multicentric study in France. The incidence of neutropenia was evaluated at each cycle of chemotherapy. Results One hundred eighty-four patients (women, 64.7 %; mean age, 61.7 years) with solid tumor (89.7 %; breast cancer, 50.5 %) or non-Hodgkin lymphoma (10.3 %) were included. The risk of febrile neutropenia based on chemotherapy regimen was >20 % for 32.1 % of patients. No case of febrile neutropenia was reported. Neutropenia was the cause of hospitalization and/or antibiotic therapy in 10 patients. The most frequent adverse events related to Zarzio^sup ^ were pain, in particular bone pain. No serious adverse event related to Zarzio^sup ^ was reported. Conclusion The results obtained in real-life conditions confirm that Zarzio^sup ^ is efficient and well tolerated in cancer patients.